Live Breaking News & Updates on Ierce pharma homepage

Stay updated with breaking news from Ierce pharma homepage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

COVID vaccines didn't get a boost from reminder texts

Text messages have proven helpful in persuading the reluctant or forgetful to get their flu shots, but these “nudges” failed to boost COVID vaccines.

Covid-19 , Igital-marketing , Pharma , Accines , Ierce-pharma-homepage , Marketing ,

In a first, FDA approves topical sirolimus for rare disease lesions

Nobelpharma America has become the first company to win FDA approval for a topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC).

Fda , Opical-gel , Opical-drug-delivery , Obelpharma , Are-diseases , Drug-delivery , Ierce-pharma-homepage , Pharma ,

Vaxxas strikes deal to tee up trial of COVID-19 vaccine patch

Vaxxas has

Vaxxas , He-university-of-texas-at-austin , Ovid-19 , Accine-patch , Drug-delivery , Harma , Eals , Ierce-pharma-homepage , Pharma ,

Bristol Myers CEO Caforio takes pay cut as 'human capital' metric drags down bonus

Bristol Myers Squibb is hoping new launches will offset a wave of forthcoming patent losses for some of its biggest-selling drugs.

Bristol-myers-squibb , Iovanni-caforio , Eo-pay , Harma-ceo , Executives , Ierce-pharma-homepage , Pharma ,

Fierce Pharma Asia—FDA oncology czar on China PD-1 rebuff; US Senate's supply chain bill; Insilico's AI targets

Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, defended the agency's rejection of Eli Lilly and Innovent Biologics' PD-1 inhibitor. The U.S.

Richard-pazdur , Hina , Apan , D-1-l1 , Ndia , Upply-chain , Ierce-pharma-asia , Li-lilly , Nnovent , Nsilico-medicine , Da-inspection

As Lilly, Innovent hit FDA rebuff, another China-made PD-1 cancer drug faces possible delay

After the FDA snubbed Eli Lilly and Innovent Biologics’ cancer immunotherapy sintilimab because of China-only data, all eyes have turned to the next China-developed PD-1 therapy in line at the FDA.

Coherus , Unshi-biosciences , D-1-l1 , Ead-and-neck-cancer , Mmuno-oncology , Hina , Da-inspection , Anofi , Nnovent-biologics , Heckpoint-inhibitors , Asia

Sanofi CEO Hudson's 2021 pay dips no thanks to lagging vaccine sales in US, China

A termination and a delay: Vaccine giant Sanofi’s COVID-19 programs had a rough year. And the French pharma’s CEO pay also suffered.

Sanofi , Aul-hudson , Eo-pay , Executives , Ierce-pharma-homepage , Pharma ,

Seeking to shake up eye inflammation market, Optifye and DelSiTech partner on controlled-release drops

Optifye Therapeutics has

Dexamethasone , Cular-drug-delivery , Ontrolled-release-drug-delivery , Drug-delivery , Eals , Ierce-pharma-homepage , Pharma ,

Fierce Pharma Asia—Chinese biotech's Pfizer trade secret suit; Lilly, Innovent's FDA rebuff; Aurobindo's New Jersey closure

The co-founders of a Chinese biotech have countersued their former employer Pfizer in a legal battle over alleged trade secret theft.

Fierce-pharma-asia , Fizer , Rade-secrets , Li-lilly , Nnovent , Omplete-response-letter , D-1-l1 , Urobindo-pharma , Lant-closure , Ayoffs , Hina

Eli Lilly, Innovent hit with FDA rejection for China-developed lung cancer drug after tough review

The other shoe has dropped for Eli Lilly and Innovent Biologics’ bid to introduce a China-developed cancer immunotherapy to the U.S. market.

Eli-lilly , Nnovent , D-1-l1 , On-small-cell-lung-cancer , Omplete-response-letter , Hina , Heckpoint-inhibitors , Ncology-drugs , Asia , Ierce-pharma-homepage , Pharma